These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 18330611

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
    Alty JE, Monaghan TM, Bamford JM.
    Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders.
    Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM.
    Swiss Med Wkly; 2002 Jul 27; 132(29-30):414-22. PubMed ID: 12428187
    [Abstract] [Full Text] [Related]

  • 5. Behçet's syndrome: from aetiology to treatment.
    Powell RJ.
    Adv Exp Med Biol; 2003 Jul 27; 528():481-6. PubMed ID: 12918749
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
    Watanabe S, Aizawa-Yashiro T, Tsuruga K, Kinjo M, Ito E, Tanaka H.
    Rheumatol Int; 2013 Dec 27; 33(12):3105-8. PubMed ID: 23266507
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New approaches in the treatment of Adamantiades-Behçet's disease.
    Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C.
    Curr Opin Rheumatol; 2006 Jan 27; 18(1):3-9. PubMed ID: 16344613
    [Abstract] [Full Text] [Related]

  • 12. Etanercept in the treatment of intestinal Behcet's disease.
    Ma D, Zhang CJ, Wang RP, Wang L, Yang H.
    Cell Biochem Biophys; 2014 Jul 27; 69(3):735-9. PubMed ID: 24622940
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
    Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H.
    Rheumatology (Oxford); 2007 May 27; 46(5):736-41. PubMed ID: 17403712
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Laryngeal involvement in Behcet's disease--a challenge for treatment.
    Gross M, Ben-Chetrit E.
    Clin Rheumatol; 2013 Mar 27; 32 Suppl 1():S75-7. PubMed ID: 20532579
    [Abstract] [Full Text] [Related]

  • 19. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J, Cheon JH.
    Gut Liver; 2018 Nov 15; 12(6):623-632. PubMed ID: 29788675
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.